NR 565 Midterm: Advanced Pharmacology (Latest
2026/2027 Update) 212 Questions & Verified
Important Considerations:
1. Academic Integrity: Using or sharing actual exam questions from a
current course would violate academic integrity policies at most
institutions.
2. Reliability Concerns: Claims of "latest 2026/2027 update" for materials
shared online are often inaccurate and may contain errors.
3. Learning Focus: The best approach is to master the concepts through:
o Official course materials and textbooks
o Lectures and class notes
o Recommended study guides
o Practice questions provided by your instructor
Legitimate Study Strategies for NR 565:
Review your pharmacology textbooks and lecture notes
Focus on key therapeutic areas covered in your syllabus
Understand drug classifications, mechanisms, indications,
contraindications, and monitoring
Practice with concept-based questions rather than seeking specific exam
content
Form study groups with classmates
, Consult your professor for recommended study resources
Core Pillars of Advanced Pharmacology (NR 565
Focus)
Your exam will likely test your ability to apply knowledge, not
just recall facts. Focus on the "why" behind decisions.
1. Pharmacokinetics & Pharmacodynamics (Advanced
Application)
Therapeutic Index & Clinical Monitoring: Know drugs with a
narrow therapeutic index (e.g., digoxin, warfarin, lithium,
phenytoin, aminoglycosides). What do you monitor (lab
values, signs/symptoms)?
Drug-Drug & Drug-Food Interactions: Mechanisms (CYP450
inducers/inhibitors). Classic example: Warfarin interactions
(with antibiotics, leafy greens, etc.).
Special Populations:
o Renal Impairment: Dose adjustments. Know drugs primarily
renally excreted (e.g., penicillin G, vancomycin, metformin,
lithium). Estimating renal function (CrCl calculations).
o Hepatic Impairment: Caution with drugs metabolized by the
liver. Child-Pugh Score application.
o Geriatrics & Pediatrics: Altered PK/PD (e.g., increased body
fat, decreased renal function in elderly; varying absorption and
metabolism in children).
2. Infectious Disease & Antimicrobial Stewardship (A
MAJOR TOPIC)
Selecting the Right Agent: Based on suspected organism, site
of infection, local resistance patterns.
, Spectrum of Activity: Broad vs. narrow-spectrum. When to use
each.
Key Drug Classes & Prototypes:
o Beta-Lactams (Penicillins, Cephalosporins,
Carbapenems): Allergies (cross-reactivity), time-dependent
killers.
o Fluoroquinolones (e.g., ciprofloxacin, levofloxacin): Black
box warnings (tendon rupture, CNS effects, hypoglycemia).
o Macrolides (e.g., azithromycin): QT prolongation risk.
o Vancomycin: Monitoring trough levels, "Red Man Syndrome."
o Antifungals (e.g., fluconazole, terbinafine): Drug interactions
(azole inhibitors of CYP450).
Resistance Mechanisms: MRSA, VRE, ESBL. Know the drugs of
choice for resistant organisms (e.g., daptomycin for
VRE, linezolid for MRSA).
3. Chronic Disease Management
Hypertension & Heart Failure:
o ACE Inhibitors (e.g., lisinopril): Dry cough, angioedema,
hyperkalemia. First-line in HFrEF.
o ARBs (e.g., losartan): Alternative to ACEi.
o Beta-Blockers: Cardioselective (metoprolol, atenolol) vs.
non-selective (propranolol). Which ones are proven in HF
(carvedilol, metoprolol succinate)?
o Diuretics: Loop (furosemide), Thiazide (HCTZ), K+-sparing
(spironolactone). Indications, key side effects (ototoxicity,
hypokalemia, hyperkalemia).
Diabetes (Type 2):
o Metformin: First-line. Mechanism, side effect (GI upset, rare
lactic acidosis), contraindication (renal impairment).
, o SGLT2 Inhibitors (e.g., empagliflozin): CV and renal benefits.
Side effect: genital mycotic infections, risk of EU/DKA.
o GLP-1 Agonists (e.g., semaglutide): CV benefits, weight loss.
Side effect: GI nausea, pancreatitis risk.
o Insulin: Onset/peak/duration of rapid, short, intermediate, and
long-acting.
Mental Health:
o SSRIs/SNRIs (e.g., sertraline, venlafaxine): First-line for
depression/anxiety. Side effects: activation, sexual dysfunction,
serotonin syndrome risk.
o Atypical Antipsychotics (e.g., quetiapine,
aripiprazole): Metabolic side effects (weight gain, dyslipidemia,
diabetes). Monitoring required.
o Benzodiazepines (e.g., lorazepam): Short-term use only.
Risks: dependence, falls, cognitive impairment.
4. Pain Management & Controlled Substances
OPIOID PRESCRIBING IS A HIGH-YIELD TOPIC.
o CDC Guidelines: Goals, initiation, titration, monitoring.
o Morphine Milligram Equivalents (MME): Calculation and its
importance in risk assessment.
o Risk Mitigation: PDMP checks, urine drug screens, treatment
agreements.
o Opioid Antagonist: Naloxone - prescribing concurrently.
Adjuvants for Neuropathic Pain: Gabapentin/pregabalin,
SNRIs (duloxetine), TCAs (amitriptyline).
5. Women's & Men's Health
Contraception: Estrogen-containing (CHCs) vs. progestin-
only. Absolute contraindications for estrogen (e.g., history of
VTE, migraines with aura).
2026/2027 Update) 212 Questions & Verified
Important Considerations:
1. Academic Integrity: Using or sharing actual exam questions from a
current course would violate academic integrity policies at most
institutions.
2. Reliability Concerns: Claims of "latest 2026/2027 update" for materials
shared online are often inaccurate and may contain errors.
3. Learning Focus: The best approach is to master the concepts through:
o Official course materials and textbooks
o Lectures and class notes
o Recommended study guides
o Practice questions provided by your instructor
Legitimate Study Strategies for NR 565:
Review your pharmacology textbooks and lecture notes
Focus on key therapeutic areas covered in your syllabus
Understand drug classifications, mechanisms, indications,
contraindications, and monitoring
Practice with concept-based questions rather than seeking specific exam
content
Form study groups with classmates
, Consult your professor for recommended study resources
Core Pillars of Advanced Pharmacology (NR 565
Focus)
Your exam will likely test your ability to apply knowledge, not
just recall facts. Focus on the "why" behind decisions.
1. Pharmacokinetics & Pharmacodynamics (Advanced
Application)
Therapeutic Index & Clinical Monitoring: Know drugs with a
narrow therapeutic index (e.g., digoxin, warfarin, lithium,
phenytoin, aminoglycosides). What do you monitor (lab
values, signs/symptoms)?
Drug-Drug & Drug-Food Interactions: Mechanisms (CYP450
inducers/inhibitors). Classic example: Warfarin interactions
(with antibiotics, leafy greens, etc.).
Special Populations:
o Renal Impairment: Dose adjustments. Know drugs primarily
renally excreted (e.g., penicillin G, vancomycin, metformin,
lithium). Estimating renal function (CrCl calculations).
o Hepatic Impairment: Caution with drugs metabolized by the
liver. Child-Pugh Score application.
o Geriatrics & Pediatrics: Altered PK/PD (e.g., increased body
fat, decreased renal function in elderly; varying absorption and
metabolism in children).
2. Infectious Disease & Antimicrobial Stewardship (A
MAJOR TOPIC)
Selecting the Right Agent: Based on suspected organism, site
of infection, local resistance patterns.
, Spectrum of Activity: Broad vs. narrow-spectrum. When to use
each.
Key Drug Classes & Prototypes:
o Beta-Lactams (Penicillins, Cephalosporins,
Carbapenems): Allergies (cross-reactivity), time-dependent
killers.
o Fluoroquinolones (e.g., ciprofloxacin, levofloxacin): Black
box warnings (tendon rupture, CNS effects, hypoglycemia).
o Macrolides (e.g., azithromycin): QT prolongation risk.
o Vancomycin: Monitoring trough levels, "Red Man Syndrome."
o Antifungals (e.g., fluconazole, terbinafine): Drug interactions
(azole inhibitors of CYP450).
Resistance Mechanisms: MRSA, VRE, ESBL. Know the drugs of
choice for resistant organisms (e.g., daptomycin for
VRE, linezolid for MRSA).
3. Chronic Disease Management
Hypertension & Heart Failure:
o ACE Inhibitors (e.g., lisinopril): Dry cough, angioedema,
hyperkalemia. First-line in HFrEF.
o ARBs (e.g., losartan): Alternative to ACEi.
o Beta-Blockers: Cardioselective (metoprolol, atenolol) vs.
non-selective (propranolol). Which ones are proven in HF
(carvedilol, metoprolol succinate)?
o Diuretics: Loop (furosemide), Thiazide (HCTZ), K+-sparing
(spironolactone). Indications, key side effects (ototoxicity,
hypokalemia, hyperkalemia).
Diabetes (Type 2):
o Metformin: First-line. Mechanism, side effect (GI upset, rare
lactic acidosis), contraindication (renal impairment).
, o SGLT2 Inhibitors (e.g., empagliflozin): CV and renal benefits.
Side effect: genital mycotic infections, risk of EU/DKA.
o GLP-1 Agonists (e.g., semaglutide): CV benefits, weight loss.
Side effect: GI nausea, pancreatitis risk.
o Insulin: Onset/peak/duration of rapid, short, intermediate, and
long-acting.
Mental Health:
o SSRIs/SNRIs (e.g., sertraline, venlafaxine): First-line for
depression/anxiety. Side effects: activation, sexual dysfunction,
serotonin syndrome risk.
o Atypical Antipsychotics (e.g., quetiapine,
aripiprazole): Metabolic side effects (weight gain, dyslipidemia,
diabetes). Monitoring required.
o Benzodiazepines (e.g., lorazepam): Short-term use only.
Risks: dependence, falls, cognitive impairment.
4. Pain Management & Controlled Substances
OPIOID PRESCRIBING IS A HIGH-YIELD TOPIC.
o CDC Guidelines: Goals, initiation, titration, monitoring.
o Morphine Milligram Equivalents (MME): Calculation and its
importance in risk assessment.
o Risk Mitigation: PDMP checks, urine drug screens, treatment
agreements.
o Opioid Antagonist: Naloxone - prescribing concurrently.
Adjuvants for Neuropathic Pain: Gabapentin/pregabalin,
SNRIs (duloxetine), TCAs (amitriptyline).
5. Women's & Men's Health
Contraception: Estrogen-containing (CHCs) vs. progestin-
only. Absolute contraindications for estrogen (e.g., history of
VTE, migraines with aura).
